Lung Cancer | Specialty

The lung cancer condition center is a comprehensive resource for clinical news and expert insights on lung cancer. Read more at OncLive.

VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD

December 5th 2025

Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

Dr Jänne on the Design of the FLAURA2 Trial of Osimertinib Plus Chemotherapy in EGFR+ NSCLC

December 3rd 2025

Pasi A. Jänne, MD, PhD, discusses the design of the FLAURA2 trial in EGFR+ NSCLC.

Silevertinib Drives CNS Responses in First-Line NSCLC With Non-Classical EGFR Mutations

December 3rd 2025

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD

December 1st 2025

Drs Sands and Shah discuss LEMS symptom identification and what guidelines currently note as best practices for the diagnosis of this disease.

Five Under 5: Top Oncology Videos for the Week of 11/23

November 30th 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 11/23

November 29th 2025

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

Durvalumab Plus Concurrent Chemoradiotherapy Fails to Show PFS or OS Benefit in NSCLC

November 28th 2025

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

Dr Leal on Clinical Considerations Surrounding the Diagnosis of LEMS in Patients With Lung Cancer

November 26th 2025

Ticiana Leal, MD, discusses clinical considerations surrounding the diagnosis of LEMS in patients with lung cancer.

Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous NSCLC

November 25th 2025

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in PD-L1+ Advanced NSCLC

November 24th 2025

Sacituzumab tirumotecan plus pembrolizumab improved PFS as first-line treatment in PD-L1–positive advanced NSCLC.

Future Directions for NSCLC With PACC Mutations

November 24th 2025

Panelists discuss how novel agents and emerging strategies may further optimize sequencing and outcomes for EGFR PACC-mutated NSCLC.

Data From the FURTHER Trial in NSCLC With EGFR PACC Mutations

November 24th 2025

Panelists discuss how the FURTHER trial demonstrated firmonertinib’s efficacy and safety in patients with PACC mutations.

Five Under 5: Top Oncology Videos for the Week of 11/16

November 23rd 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 11/16

November 22nd 2025

The FDA approved 5 therapeutic options spanning lung cancer, urothelial cancer, NF1-associated PNs, and AL amyloidosis.

NDA for Zipalertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations Is Submitted to the FDA

November 21st 2025

A rolling NDA submission for zipalertinib in NSCLC with EGFR exon 20 insertion mutations who received prior chemotherapy has been initiated.

FDA Accepts NDA for Zidesamtinib in ROS1+ Advanced NSCLC After a Prior TKI

November 21st 2025

Will the FDA approve zidesamtinib for ROS1-positive advanced non–small cell lung cancer after a prior TKI?

FDA Clears Oncomine Dx Target Test as Companion Diagnostic for Sevabertinib in NSCLC

November 20th 2025

The FDA OKs the Oncomine Dx Target Test to identify patients with HER2 TKD–mutant NSCLC eligible for sevabertinib, enabling targeted treatment selection.